PBYI

Puma Biotechnology Inc

2.98 USD
-0.01 (-0.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Puma Biotechnology Inc stock is down -25.31% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.15% of the previous 12 June’s closed higher than May. 100% of analysts rate it a buy.

About Puma Biotechnology Inc

Puma Biotechnology, Inc. focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd.

  • HC Wainwright & Co.
    Tue Jun 4, 07:36
    buy
    confirm
  • HC Wainwright & Co.
    Mon Jun 3, 07:40
    buy
    confirm